COPD Foundation Inc.
https://www.copdfoundation.org/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From COPD Foundation Inc.
Asia Deal Watch: Argo Partners RNAi Programs With Novartis In Major Biobucks Pact
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Financing Quarterly Statistics, Q2 2022
During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.
IPO Update: Mid-Year Average Return Deceptively Positive In Down Market
The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice